Supernus Pharmaceuticals SUPN Investment Income Net Amortization Of Discount And Premium
Investment Income Net Amortization Of Discount And Premium at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's investment income net amortization of discount and premium.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's investment income net amortization of discount and premium?
- Supernus Pharmaceuticals (SUPN) reported investment income net amortization of discount and premium of $192K in Q1 2026.
- How has Supernus Pharmaceuticals's investment income net amortization of discount and premium changed year-over-year?
- Supernus Pharmaceuticals's investment income net amortization of discount and premium decreased by 82.1% year-over-year, from $1.07M to $192K.
- What does investment income net amortization of discount and premium mean?
- This represents the net impact of interest income earned on cash equivalents and marketable securities, adjusted for the amortization of premiums or discounts on those investments. It reflects the non-operating yield generated from the company's liquid asset portfolio. Investors use this to assess the efficiency of cash management and the return on idle capital.